Trial Profile
A Phase 1 Study of AZD6244 in Combination With Cetuximab in Refractory Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Selumetinib (Primary)
- Indications Colorectal cancer; Solid tumours
- Focus Adverse reactions; Therapeutic Use
- 14 Dec 2015 Results published in the Investigational New Drugs
- 01 Aug 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 05 Oct 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.